A. D. Brandon

发表

Molecular Cancer Therapeutics The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK 1 Inhibitor SAR-020106

M. Walton, K. Boxall, G. Aherne, 2009 .

Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition

Chris Jones, F. Hofmann, S. Robinson, 2012, Proceedings of the National Academy of Sciences.

Cancer Therapy : Preclinical AT 13148 Is a Novel , Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

P. Jones, P. Workman, M. Walton, 2012 .

A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.

B. Al-Lazikani, K. Harrington, M. Valenti, 2013, European journal of cancer.

Abstract B74: The dual FLT3-Aurora inhibitor CCT241736 overcomes resistance to selective FLT3 inhibition driven by FLT3 ligand and FLT3 point mutations in acute myeloid leukemia.

P. Workman, A. Faisal, M. Valenti, 2011 .

Preclinical Development Enhanced Efficacy of IGF 1 R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFR a / b

Chris Jones, F. Hofmann, S. Jeay, 2011 .

ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma

M. Monje, J. Mora, Chris Jones, 2019, Communications Biology.

ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma

M. Monje, J. Mora, Chris Jones, 2019, Communications Biology.

ENHANCED EFFICACY OF IGF1R INHIBITION IN PAEDIATRIC GLIOBLASTOMA BY COMBINATORIAL TARGETING OF PDGFRALPHA/BETA

Gary Box, Sergey Popov, Darren Hargrave, 2010 .

ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma

M. Monje, J. Mora, Chris Jones, 2019, Communications Biology.

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).

S. Robinson, R. V. van Montfort, M. Lamers, 2016, Journal of medicinal chemistry.

Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours

M. Leach, H. Parkes, M. Valenti, 2015, British Journal of Cancer.

Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo

P. Workman, A. Faisal, M. Valenti, 2010 .

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736,

P. Workman, A. Faisal, M. Valenti, 2011 .